NDA 021572 · Cubist Pharms LLC
Cubicin
Daptomycin · Intravenous
NovelPriority reviewDiscontinuedLast checked: Nov 19, 2026Latest source record: May 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Sep 12, 2003
Approved uses
5
Original approval plus efficacy supplements
Registered trials
94
20 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 1, 2017 Supplement 57 · Efficacy · priority review LabelLetterPediatric Clinical Pharmacology Review
- Mar 29, 2017 Supplement 55 · Efficacy · priority review LabelLetterPediatric Medical Review
- Nov 30, 2010 Supplement 23 · Efficacy LabelLetter
- May 25, 2006 Supplement 8 · Efficacy · priority review LetterReviewLabel
- Sep 12, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
- CUBICIN · DAPTOMYCIN 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued · TE AP
- CUBICIN RF · DAPTOMYCIN 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued
- CUBICIN · DAPTOMYCIN 250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Daptomycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Combination Antibiotic Therapy for Staphylococcus Aureus BacteremiaPivotal-lookingRecruiting
Intermountain Health Care, Inc.Academic, hospital or other
NCT07376889 · 2,096 participants (planned) · Start Feb 1, 2026 · Primary completion Jan 2029
Drug: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB); Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Brighton, Colorado; Denver, Colorado; Grand Junction, Colorado · 13 sites in all
- Daptomycin as Antibiotic Prophylaxis of Sternal Wound InfectionsPivotal-lookingCompleted
Hannover Medical SchoolAcademic, hospital or other
NCT01080963 · 650 participants · Start Nov 2008 · Primary completion Mar 2012
Drug: Daptomycin; Cefuroxime · For: Wound Infection
Sites: Hanover, Germany
- Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream InfectionPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT01191840 · 509 participants · Start Feb 2011 · Primary completion Mar 4, 2017
Drug: Vancomycin; Vancomycin · For: Bacteremia
Sites: Birmingham, Alabama; Los Angeles, California; Denver, Colorado · 15 sites in all
- Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure InfectionsPivotal-lookingCompleted
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00711802 · 396 participants · Start Jul 23, 2008 · Primary completion Oct 11, 2013
Drug: Daptomycin; Standard of Care (SOC) · For: Skin Diseases, Infectious
Sites: Birmingham, Alabama; Oakland, California; Orange, California · 30 sites in all
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus BacteremiaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT03138733 · 390 participants · Start Aug 26, 2018 · Primary completion Mar 11, 2022
Drug: Ceftobiprole medocaril; Daptomycin · For: Staphylococcus Aureus Bacteremia
Sites: Chula Vista, California; West Palm Beach, Florida; Butte, Montana · 60 sites in all
- Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus InfectionPivotal-lookingTerminated
Menzies School of Health ResearchAcademic, hospital or other
NCT02365493 · 358 participants · Start Aug 26, 2015 · Primary completion Oct 24, 2018
Drug: Beta-Lactam · For: Methicillin-Resistant Staphylococcus Aureus
Sites: Blacktown, Australia; Camperdown, Australia; Concord, Australia · 30 sites in all
- Ceftriaxone as Home IV for Staph InfectionsPivotal-lookingStatus unknown
Vancouver Island Health AuthorityAcademic, hospital or other
NCT04141787 · 310 participants (planned) · Start Jul 11, 2019 · Primary completion Jul 2023
Drug: Ceftriaxone; Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin) · For: Staphylococcal Infections; Osteomyelitis; CNS Infection and 5 more
Sites: Victoria, Canada · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Cubicin* (Daptomycin*) · HCPCS J0878
2024 spending
$1.9M
Beneficiaries
3,510
54,040 claims
Per beneficiary
$546
2024 ASP limit $0.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $22,794,552 |
| 2021 | $4,715,716 |
| 2022 | $2,492,714 |
| 2023 | $2,291,986 |
| 2024 | $1,918,200 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
Holland TL, Cosgrove SE, Doernberg SB, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Equivalence Trial
- Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis.
Guan L, Beig M, Wang L, et al. · Ann Clin Microbiol Antimicrob 2024 · Systematic Review, Meta-Analysis
- Antimicrobial treatment of Corynebacterium striatum invasive infections: a systematic review.
Milosavljevic MN, Milosavljevic JZ, Kocovic AG, et al. · Rev Inst Med Trop Sao Paulo 2021 · Systematic Review
- Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
Geriak M, Haddad F, Rizvi K, et al. · Antimicrob Agents Chemother 2019 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC, Lye DC, Yahav D, et al. · JAMA 2020 · Comparative Study, Multicenter Study
- Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis.
Adamu Y, Puig-Asensio M, Dabo B, et al. · PLoS One 2024 · Comparative Study, Meta-Analysis
Sponsor: Cubist Pharms LLC · Also marketed as Cubicin Rf
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.